Clinical Trial Update: Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating belantamab mafodotin in newly diagnosed, transplant-eligible multiple myeloma patients is active but not currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Blenrep (belantamab mafodotin)

Snippet

Sponsor: PETHEMA Foundation | Conditions: Multiple Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING